Opendata, web and dolomites

SenolT SIGNED

Fast and effective diagnostic test for the early detection of residual tumours to prevent cancer recurrence

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SenolT project word cloud

Explore the words cloud of the SenolT project. It provides you a very rough idea of what is the project "SenolT" about.

ebitda    clinical    radiotherapy    removing    initial    risked    newly    senolytic    treatment    monitoring    license    800    biopsy    price    total    develops    proprietary    cancers    2025    sales    breast    triple    expensive    company    slow    pancreatic    people    prognosis    lives    tumours    hard    class    patients    npv    created    protein    received    57    kinds    families    pharmaceutical    detects    innovative    royalties    liquid    negative    tumour    tnbc    tests    therapies    damaged    120    recurrence    markers    mortality    predict    competitors    usa    detection    net    population    15    healthcare    customers    technologies    contacted    share    pressing    cancer    senolt    cumulative    happen    companies    de    market    finalise    10    trials    cells    tam    poor    prevent    jobs    appear    residual    chemotherapy    pharma    44    portfolio    27    mission    discount    medicines    irr    demand    352    rate    phase2    soon    senescent    validated    20    mainly    therapeutics    diagnostic   

Project "SenolT" data sheet

The following table provides information about the project.

Coordinator
SENOLYTIC THERAPEUTICS SL 

Organization address
address: CL BALDIRI I REIXAC 4-8 PARC CIENTIFIC DE BARCELON
city: BARCELONA
postcode: 8028
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.senolytx.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2019-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SENOLYTIC THERAPEUTICS SL ES (BARCELONA) coordinator 50˙000.00

Map

 Project objective

The main concern in cancer treatment is its high rate of recurrence. It may happen soon or years after treatment and it’s very hard to predict/prevent. Removing residual tumour cells is the best way to avoid recurrence, so identifying new tumour markers is the most pressing demand. We have developed SenolT, an innovative diagnostic test for the early detection and monitoring of senescent cells, which appear after chemotherapy/radiotherapy and are directly associated to cancer recurrence. SenolT detects all kinds of tumours, but we focus on pancreatic and triple negative breast (TNBC) cancers because prognosis is very poor for patients and recurrence is their main cause of mortality. Our customers will be pharmaceutical companies, so we have already contacted several of them in the sector. The initial target market will be TNBC/Pancreatic cancer patients that received chemotherapy/radiotherapy in the EU & USA. Competitors focus on liquid biopsy tests and cancer-related protein markers (expensive & slow to get results). No other companies are working in the detection of senescent cells as a diagnostic method to predict recurrence. Senolytic Therapeutics is a company that develops a new class of medicines by targeting damaged cells. Our mission is to advance our portfolio of therapies to clinical trials and improve the lives of patients and families. Our SenolT proprietary technology will be developed and de-risked through Phase2 Clinical trials and then license the validated technologies to pharma companies, to finalise their development and bring them to the market. By 2025 we expect: A) 15% royalties’ rate on net sales with a unit price to healthcare systems of €800; B) 20% market share (70,000 people) from an expected total of TNBC/pancreatic cancer population of over 352,000 in USA & EU; C) TAM growing up to about €57 m; D) NPV of €27.2 m (10% discount rate) and an IRR of 120%; E) Cumulative EBITDA of about €44 m; F) 20 newly created jobs, mainly in R&D and sales.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SENOLT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SENOLT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More